- Home
- ELTK vs IMA Comparison
ELTK vs IMA Comparison
Compare ELTK & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELTK | IMA |
|---|---|---|
| Founded | 1970 | 2019 |
| Country | Israel | United States |
| Employees | N/A | 15 |
| Industry | Electrical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.3M | 54.8M |
| IPO Year | 1998 | N/A |
Fundamental Metrics
Financial Performance| Metric | ELTK | IMA |
|---|---|---|
| Price | $8.46 | $5.78 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 3.7K | ★ 371.8K |
| Earning Date | 05-19-2026 | 05-15-2026 |
| Dividend Yield | ★ 2.32% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.18 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $48.71 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.73 | $3.94 |
| 52 Week High | $12.19 | $17.50 |
Technical Indicators
Market Signals| Indicator | ELTK | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 49.57 | 53.84 |
| Support Level | $8.38 | $3.94 |
| Resistance Level | $9.34 | $7.28 |
| Average True Range (ATR) | 0.38 | 0.53 |
| MACD | 0.02 | 0.15 |
| Stochastic Oscillator | 68.98 | 66.30 |
Price Performance
Historical ComparisonAbout ELTK Eltek Ltd.
Eltek Ltd is engaged in the technology business sector that manufactures and supplies technologically new custom-made circuitry solutions. The company manufactures, markets, and sells custom-made printed circuit boards (PCBs), including high-density interconnect, flex-rigid and multi-layered boards. The Company markets its products mainly to the medical technology, defense and aerospace, industrial, telecom, and networking equipment industries. The geographic areas of the company are Israel, North America, the Netherlands, India, and Others. It generates the majority of its revenue from Israel.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.